SEARCH

SEARCH BY CITATION

Cited in:

CrossRef

This article has been cited by:

  1. 1
    Richard Rubenstein, Biomarkers of Brain Injury and Neurological Disorders, 2014,

    CrossRef

  2. 2
    Adem Zengin, Ugur Tamer, Tuncer Caykara, A SERS-Based Sandwich Assay for Ultrasensitive and Selective Detection of Alzheimer’s Tau Protein, Biomacromolecules, 2013, 14, 9, 3001

    CrossRef

  3. 3
    Jasmine Ramcharitar, Steffen Albrecht, Veronica M. Afonso, Vikas Kaushal, David A. Bennett, Andrea C. LeBlanc, Cerebrospinal Fluid Tau Cleaved by Caspase-6 Reflects Brain Levels and Cognition in Aging and Alzheimer Disease, Journal of Neuropathology & Experimental Neurology, 2013, 72, 9, 824

    CrossRef

  4. 4
    Enrica Cavedo, Annapaola Prestia, Cognitive decline and cerebrospinal fluid biomarkers: a close relationship, Future Neurology, 2013, 8, 4, 403

    CrossRef

  5. 5
    Kiarach Mesbah, Farid Oukacine, Stefan Lehnert, Markus Otto, Myriam Taverna, On-line capillary electrophoresis derivatization method for high sensitivity analysis of ubiquitin in filtered cerebrospinal fluid, ELECTROPHORESIS, 2013, 34, 18
  6. 6
    M Di Carlo, D Giacomazza, P L San Biagio, Alzheimer’s disease: biological aspects, therapeutic perspectives and diagnostic tools, Journal of Physics: Condensed Matter, 2012, 24, 24, 244102

    CrossRef

  7. 7
    Erik Stomrud, Anton Forsberg, Douglas Hägerström, Erik Ryding, Kaj Blennow, Henrik Zetterberg, Lennart Minthon, Oskar Hansson, Elisabet Londos, CSF Biomarkers Correlate with Cerebral Blood Flow on SPECT in Healthy Elderly, Dementia and Geriatric Cognitive Disorders, 2012, 33, 2-3, 156

    CrossRef

  8. 8
    Michael Jonsson, Henrik Zetterberg, Sindre Rolstad, Ake Edman, Alida A. Gouw, Maria Bjerke, Karin Lind, Kaj Blennow, Leonardo Pantoni, Domenico Inzitari, Anders Wallin, Low Cerebrospinal Fluid Sulfatide Predicts Progression of White Matter Lesions – The LADIS Study, Dementia and Geriatric Cognitive Disorders, 2012, 34, 1, 61

    CrossRef

  9. 9
    Ann D. Cohen, Gil D. Rabinovici, Chester A. Mathis, William J. Jagust, William E. Klunk, Milos D. Ikonomovic, Current State of Alzheimer's Disease Research and Therapeutics, 2012,

    CrossRef

  10. 10
    Shorena Samakashvili, Clara Ibáñez, Carolina Simó, Francisco J. Gil-Bea, Bengt Winblad, Angel Cedazo-Mínguez, Alejandro Cifuentes, Analysis of chiral amino acids in cerebrospinal fluid samples linked to different stages of Alzheimer disease, ELECTROPHORESIS, 2011, 32, 19
  11. 11
    David M. Holtzman, CSF biomarkers for Alzheimer's disease: current utility and potential future use, Neurobiology of Aging, 2011, 32, S4

    CrossRef

  12. 12
    Christian Humpel, Identifying and validating biomarkers for Alzheimer's disease, Trends in Biotechnology, 2011, 29, 1, 26

    CrossRef

  13. 13
    Jihye Choi, Ho-Won Lee, Kyoungho Suk, Increased plasma levels of lipocalin 2 in mild cognitive impairment, Journal of the Neurological Sciences, 2011, 305, 1-2, 28

    CrossRef

  14. 14
    Javier L. Urraca, Carla S. A. Aureliano, Eric Schillinger, Hermann Esselmann, Jens Wiltfang, Börje Sellergren, Polymeric Complements to the Alzheimer's Disease Biomarker β-Amyloid Isoforms Aβ1–40 and Aβ1–42 for Blood Serum Analysis under Denaturing Conditions, Journal of the American Chemical Society, 2011, 133, 24, 9220

    CrossRef

  15. 15
    Rawan Tarawneh, David M. Holtzman, Biomarkers in translational research of Alzheimer’s Disease, Neuropharmacology, 2010, 59, 4-5, 310

    CrossRef

  16. 16
    Josef Zihl, Simone Reppermund, Sonja Thum, Kathrin Unger, Neuropsychological profiles in MCI and in depression: Differential cognitive dysfunction patterns or similar final common pathway disorder?, Journal of Psychiatric Research, 2010, 44, 10, 647

    CrossRef

  17. 17
    Erik Stomrud, Oskar Hansson, Lennart Minthon, Kaj Blennow, Ingmar Rosén, Elisabet Londos, Slowing of EEG correlates with CSF biomarkers and reduced cognitive speed in elderly with normal cognition over 4 years, Neurobiology of Aging, 2010, 31, 2, 215

    CrossRef

  18. 18
    RAMUNE GRAMBAITE, VIDAR STENSET, IVAR REINVANG, KRISTINE B. WALHOVD, ANDERS M. FJELL, TORMOD FLADBY, White matter diffusivity predicts memory in patients with subjective and mild cognitive impairment and normal CSF total tau levels, Journal of the International Neuropsychological Society, 2010, 16, 01, 58

    CrossRef

  19. 19
    Christoph Zenzmaier, Josef Marksteiner, Andreas Kiefer, Peter Berger, Christian Humpel, Dkk-3 is elevated in CSF and plasma of Alzheimer’s disease patients, Journal of Neurochemistry, 2009, 110, 2
  20. 20
    Lidia Glodzik-Sobanska, Elizabeth Pirraglia, Miroslaw Brys, Susan de Santi, Lisa Mosconi, Kenneth E. Rich, Remigiusz Switalski, Leslie Saint Louis, Martin J. Sadowski, Frank Martiniuk, Pankaj Mehta, Domenico Pratico, Raymond P. Zinkowski, Kaj Blennow, Mony J. de Leon, The effects of normal aging and ApoE genotype on the levels of CSF biomarkers for Alzheimer's disease, Neurobiology of Aging, 2009, 30, 5, 672

    CrossRef

  21. 21
    Nicolas Sergeant, Alexis Bretteville, Malika Hamdane, Marie-Laure Caillet-Boudin, Pierre Grognet, Stephanie Bombois, David Blum, André Delacourte, Florence Pasquier, Eugeen Vanmechelen, Susanna Schraen-Maschke, Luc Buée, Biochemistry of Tau in Alzheimer’s disease and related neurological disorders, Expert Review of Proteomics, 2008, 5, 2, 207

    CrossRef

  22. 22
    ARTO NORDLUND, SINDRE ROLSTAD, OLA KLANG, KARIN LIND, MONA PEDERSEN, KAJ BLENNOW, ÅKE EDMAN, STEFAN HANSEN, ANDERS WALLIN, Episodic memory and speed/attention deficits are associated with Alzheimer-typical CSF abnormalities in MCI, Journal of the International Neuropsychological Society, 2008, 14, 04

    CrossRef

  23. 23
    Jesús Poza, Roberto Hornero, Daniel Abásolo, Alberto Fernández, Agustín Mayo, Evaluation of spectral ratio measures from spontaneous MEG recordings in patients with Alzheimer's disease, Computer Methods and Programs in Biomedicine, 2008, 90, 2, 137

    CrossRef

  24. 24
    Christin Andersson, Kaj Blennow, Ove Almkvist, Niels Andreasen, Peter Engfeldt, Sven-Erik Johansson, Maria Lindau, Maria Eriksdotter-Jönhagen, Increasing CSF phospho-tau levels during cognitive decline and progression to dementia, Neurobiology of Aging, 2008, 29, 10, 1466

    CrossRef

  25. 25
    Andre Delacourte, Dementias, 2008,

    CrossRef

  26. 26
    Kiyoko S. Murayama, Fuyuki Kametani, Takeshi Tabira, Wataru Araki, A novel monoclonal antibody specific for the amino-truncated β-amyloid Aβ5-40/42 produced from caspase-cleaved amyloid precursor protein, Journal of Neuroscience Methods, 2007, 161, 2, 244

    CrossRef

  27. 27
    Hope T. Beier, Christopher B. Cowan, I-Hsien Chou, James Pallikal, James E. Henry, Melodie E. Benford, Joseph B. Jackson, Theresa A. Good, Gerard L. Coté, Application of Surface-Enhanced Raman Spectroscopy for Detection of Beta Amyloid Using Nanoshells, Plasmonics, 2007, 2, 2, 55

    CrossRef

  28. 28
    Z A Rodd, B A Bertsch, W N Strother, H Le-Niculescu, Y Balaraman, E Hayden, R E Jerome, L Lumeng, J I Nurnberger, H J Edenberg, W J McBride, A B Niculescu, Candidate genes, pathways and mechanisms for alcoholism: an expanded convergent functional genomics approach, The Pharmacogenomics Journal, 2007, 7, 4, 222

    CrossRef

  29. 29
    A. Ågren-Wilsson, A. Lekman, W. Sjöberg, L. Rosengren, K. Blennow, A. T. Bergenheim, J. Malm, CSF biomarkers in the evaluation of idiopathic normal pressure hydrocephalus, Acta Neurologica Scandinavica, 2007, 116, 5
  30. 30
    Jacques Touchon, Florence Portet, Mild Cognitive Impairment, La Presse Médicale, 2007, 36, 10, 1464

    CrossRef

  31. 31
    Laura A. Rabin, Andrew J. Saykin, Heather A. Wishart, Katherine E. Nutter-Upham, Laura A. Flashman, Nadia Pare, Robert B. Santulli, The Memory and Aging Telephone Screen: Development and preliminary validation, Alzheimer's & Dementia, 2007, 3, 2, 109

    CrossRef

  32. 32
    Gregory A. Jicha, Ronald C. Petersen, The Dementias 2, 2007,

    CrossRef

  33. 33
    Vincenzo Solfrizzi, Alessia D'Introno, Anna Maria Colacicco, Cristiano Capurso, Orlando Todarello, Vincenza Pellicani, Sabrina A Capurso, Giuseppe Pietrarossa, Vito Santamato, Antonio Capurso, Francesco Panza, Circulating biomarkers of cognitive decline and dementia, Clinica Chimica Acta, 2006, 364, 1-2, 91

    CrossRef

  34. 34
    Bernhard H Monien, Liana G Apostolova, Gal Bitan, Early diagnostics and therapeutics for Alzheimer’s disease – how early can we get there?, Expert Review of Neurotherapeutics, 2006, 6, 9, 1293

    CrossRef

  35. 35
    Koichi Inoue, Carlos Garner, Bradley L. Ackermann, Tomoyuki Oe, Ian A. Blair, Liquid chromatography/tandem mass spectrometry characterization of oxidized amyloid beta peptides as potential biomarkers of Alzheimer's disease, Rapid Communications in Mass Spectrometry, 2006, 20, 5
  36. 36
    Marilyn S. Albert, Deborah Blacker, Mild Cognitive Impairment and Dementia, Annual Review of Clinical Psychology, 2006, 2, 1, 379

    CrossRef

  37. 37
    Allan Levey, James Lah, Felicia Goldstein, Kyle Steenland, Donald Bliwise, Mild cognitive impairment: An opportunity to identify patients at high risk for progression to Alzheimer's disease, Clinical Therapeutics, 2006, 28, 7, 991

    CrossRef

  38. 38
    M. Sepe-Monti, A. De Carolis, G. Bomboi, P. Castri, F. Giubilei, MRI evidence of bilateral hippocampal sclerosis in amnestic mild cognitive impairment, European Journal of Neurology, 2006, 13, 9
  39. 39
    Barbara Borroni, Monica Di Luca, Alessandro Padovani, Predicting Alzheimer dementia in mild cognitive impairment patients, European Journal of Pharmacology, 2006, 545, 1, 73

    CrossRef

  40. 40
    Mun’delanji Vestergaard, Kagan Kerman, Eiichi Tamiya, The study of Alzheimer’s disease biomarkers, NanoBiotechnology, 2006, 2, 1-2, 5

    CrossRef

  41. 41
    Kurt Jellinger, The Dementias, 2006,

    CrossRef

  42. 42
    Current awareness in geriatric psychiatry, International Journal of Geriatric Psychiatry, 2005, 20, 5
  43. 43
    D. G. Georganopoulou, L. Chang, J.-M. Nam, C. S. Thaxton, E. J. Mufson, W. L. Klein, C. A. Mirkin, From The Cover: Nanoparticle-based detection in cerebral spinal fluid of a soluble pathogenic biomarker for Alzheimer's disease, Proceedings of the National Academy of Sciences, 2005, 102, 7, 2273

    CrossRef

  44. 44
    Pierre Lescuyer, Alberto Gandini, Pierre R. Burkhard, Denis F. Hochstrasser, Jean-Charles Sanchez, Prostaglandin D2 synthase and its post-translational modifications in neurological disorders, ELECTROPHORESIS, 2005, 26, 23
  45. 45
    Marco Pugliese, Josep Lluis Carrasco, Carmen Andrade, Ernesto Mas, Joan Mascort, Nicole Mahy, Severe cognitive impairment correlates with higher cerebrospinal fluid levels of lactate and pyruvate in a canine model of senile dementia, Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2005, 29, 4, 603

    CrossRef

  46. 46
    Susanne G. Mueller, Michael W. Weiner, Leon J. Thal, Ronald C. Petersen, Clifford Jack, William Jagust, John Q. Trojanowski, Arthur W. Toga, Laurel Beckett, The Alzheimer's Disease Neuroimaging Initiative, Neuroimaging Clinics of North America, 2005, 15, 4, 869

    CrossRef

  47. 47
    Hayrettin Tumani, Johannes Brettschneider, ZNS-Proteine im Liquor: Einflussfaktoren auf ihre Konzentration im Liquor und klinische Relevanz Brain specific proteins in cerebrospinal fluid (CSF): factors influencing their concentration in CSF and clinical relevance, LaboratoriumsMedizin, 2005, 29, 6, 421

    CrossRef

  48. 48
    Winblad B, Palmer K, Kivipelto M, Jelic V, Fratiglioni L, Introduction: Mild cognitive impairment: beyond controversies, towards a consensus, Journal of Internal Medicine, 2004, 256, 3